Becton, Dickinson, and Company, or BD, has announced the commercial release of the BD OMICS-One XT WTA Assay, its first robotics-compatible high-throughput reagent kit. Created in partnership with Hamilton, a leader in lab automation, this new solution aims to streamline the traditionally manual and time-consuming DNA library preparation process required in single-cell discovery studies. The solution integrates BD’s reagent kits with Hamilton’s Microlab NGS STAR automated liquid handling platform, allowing researchers to accelerate and scale genomics workflows while minimizing the variability and human error often associated with manual procedures. With Hamilton's NGS STAR system already widely installed globally, the new reagent kits offer seamless integration for labs looking to enhance genomics throughput and reliability.
BD, one of the world’s largest medical technology companies, is committed to advancing healthcare through innovative solutions for medical discovery, diagnostics, and treatment. With over 70,000 employees worldwide, BD supports healthcare professionals, laboratory scientists, and researchers in their pursuit of new therapies and diagnostics. The company’s collaborative approach and expansive product portfolio aim to improve healthcare outcomes, reduce costs, and increase accessibility globally. This new automation-ready technology reinforces BD’s dedication to advancing single-cell research, particularly in crucial fields like oncology and immunology.
